Citation Impact
Citing Papers
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE
2013 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2007 Standout
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome
2004
Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis
2004
Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia
2006
A comparison of the efficacy and safety of inhaled corticosteroids in asthma
1997
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
2000 Standout
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia
2002
Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal Pneumonia
2001
Global Initiative for Chronic Obstructive Lung Disease
2002 Standout
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies
2004
Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis
2015
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
2003 Standout
Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD
2000
The Etiology of Community‐Acquired Pneumonia in Australia: Why Penicillin plus Doxycycline or a Macrolide Is the Most Appropriate Therapy
2008
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Assessment of bias in outcomes reported in trials on pneumonia: a systematic review
2013
Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections
2006 Standout
DIAGNOSIS AND TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION
1997 Standout
Five Versus Ten Days Treatment of Streptococcal Pharyngotonsillitis: A Randomized Controlled Trial Comparing Cefpodoxime Proxetil and Phenoxymethyl Penicillin
1994
Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010
2010 Standout
The cytokine storm of severe influenza and development of immunomodulatory therapy
2015 Standout
Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections
2001
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
2009
Different antibiotic treatments for group A streptococcal pharyngitis
2013
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
A Randomized Study of Sequential Intravenous/Oral Moxifloxacin in Comparison to Sequential Intravenous Ceftriaxone/Oral Cefuroxime Axetil in Patients with Hospital-Acquired Pneumonia
2007
Antibacterial Therapy for Acute Group A Streptococcal Pharyngotonsillitis
2002
Global strategy for asthma management and prevention: GINA executive summary
2007 Standout
Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases
2011
Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections
2001
One-year cost-effectiveness of tiotropiumversusipratropium to treat chronic obstructive pulmonary disease
2004
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
2010 Standout
Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis
2004
Implications for Macrolide Treatment in Community-Acquired Pneumonia
1998
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
2004 Standout
Moxifloxacin
2004
A Retrospective Comparison of Ceftriaxone Versus Oxacillin for Osteoarticular Infections Due to Methicillin-Susceptible Staphylococcus aureus
2011
Disordered Microbial Communities in Asthmatic Airways
2010 Standout
Guidelines for the management of adult lower respiratory tract infections
2005
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2001 Standout
Guidelines for the Management of Adults with Community-acquired Pneumonia
2001 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review
2001
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
2003 Standout
Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community‐Acquired Pneumonia
2008
Antibiotics for community-acquired pneumonia in adult outpatients
2014
Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
2000
Interventions for enhancing medication adherence
2008 Standout
Legionella and Legionnaires' Disease: 25 Years of Investigation
2002 Standout
The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003
2003 Standout
Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study
2006
Interventions for enhancing medication adherence
2014 Standout
Different antibiotic treatments for group A streptococcal pharyngitis
2016
Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease
2006
COVID-19 and its implications for thrombosis and anticoagulation
2020 Standout
Antibiotics for sore throat
2013 Standout
Clinical Practice Guideline (Update): Adult Sinusitis
2015 Standout
Prosthetic Joint Infection
2014 Standout
Use of Inhaled Corticosteroids and Risk of Fractures
2001 Standout
Clinical practice guideline: Adult sinusitis
2007 Standout
Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America
2012 Standout
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults
2003
Industry sponsorship and research outcome
2017 Standout
Pharmacoeconomic Benefit of Antibiotic Step-Down Therapy: Converting Patents from Intravenous Ceftriaxone to Oral Cefpodoxime Proxettl
1995
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China
2020 Standout
Works of P. Zück being referenced
Utilisation de la clarithromycine à libération modifiée en traitement court des exacerbations aiguës d’une BPCO peu grave en pratique médicale courante
2008
Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia
1990
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors
2005
Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
1999
A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A β-haemolytic streptococci
1995
Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis
1990
Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.
2002
[Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day?].
2000
Equally efficacious asthma management with budesonide 800 micrograms administered by Turbuhaler or with beclomethasone dipropionate > or = 1500 micrograms given through a pressurized metered-dose inhaler with spacer. The French Budesonide Trial Group.
1996
[Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess. Apropos of 57 cases].
1993
Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment
2002